전남대학교 중앙도서관

  • 중앙도서관
  • 여수캠퍼스도서관
  • 법학도서관
  • 치의학도서관
  • 의학도서관

링크메뉴

  • 화면키우기 화면줄이기 화면크기 원래대로
  • S
  • HOME
  • 로그인
  • 전남대
  • ENG
  • CHN

주메뉴

전체메뉴

전자자료 상세검색

전자자료 상세검색

통합검색
상세검색
검색어 [키워드: "Seffar E"]
총 8건 
※ 중복 레코드가 제거된 검색 결과가 표시됩니다.
1/1 페이지 RSS 엑셀파일 출력
검색결과수정
  • 검색범위확장
    • Full Text내 키워드 확장
    • 관련 주제어 확장

    재검색

  • 검색결과제한
    • 원문(Full Text)
    • Peer-Reviewed 학술지
    • 발행년 -

    재검색

  • 자료유형
    • Academic Journals (8)

    재검색

  • 주제
    • carcinoma, non-small-cell lung (1)
    • colorectal neoplasms (1)
    • immunotherapy, adoptive (1)

    더보기

    재검색

  • 간행물
    • immuno-oncology and technology (2)
    • biorxiv the preprint server for biology (1)
    • cancer immunology immunotherapy cii (1)

    더보기

    재검색

  • 출판사
    • elsevier ltd (2)
    • bmj publishing group ltd (1)
    • chinese society of immunology;; _b nature pub. group (1)

    더보기

    재검색

  • 언어
    • english (8)

    재검색

  • 수록데이터베이스
    • MEDLINE (6)
    • ScienceDirect (2)

    재검색

  • PQDTSearch
  • CAJSearch
  • RISSSearch
  • PsycINFOSearch

 

3
CAR-T cells targeting IL-1RAP produced in a closed semiautomatic system are ready for the first phase I clinical investigation in humans. 미리보기

학술저널

issue
Current research in translational medicine [Curr Res Transl Med] 2023 Apr-Jun; Vol. 71 (2), pp. 103385. Date of Electronic Publication: 2023 Feb 04.
Author
Nicod C; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
da Rocha MN; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; CanCell Therapeutics, 25000 Besançon, France.
Warda W; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; CanCell Therapeutics, 25000 Besançon, France.
Roussel X; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Hematology, CHU Besançon, F-25000 Besançon, France.
Haderbache R; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Seffar E; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Trad R; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Bouquet L; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Goncalves M; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Lymphobank S.A.S.U, F-25000 Besançon, France.
Bosdure L; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Laude MC; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Guiot M; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.
Ferrand C; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; CanCell Therapeutics, 25000 Besançon, France.
Deschamps M; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; CanCell Therapeutics, 25000 Besançon, France. Electronic address: christophe.ferrand@efs.sante.fr.
DB Label
Database : MEDLINE
원문보기
Full Text (ScienceDirect)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
4
CD8 + CD226 high T cells in liver metastases dictate the prognosis of colorectal cancer patients treated with chemotherapy and radical surgery. 미리보기

학술저널

issue
Cellular & molecular immunology [Cell Mol Immunol] 2023 Apr; Vol. 20 (4), pp. 365-378. Date of Electronic Publication: 2023 Jan 30.
Author
Viot J; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, Besançon, France. jviot@chu-besancon.fr.; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France. jviot@chu-besancon.fr.
Abdeljaoued S; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Vienot A; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, Besançon, France.; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Seffar E; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Spehner L; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, Besançon, France.; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Bouard A; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Asgarov K; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Pallandre JR; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Renaude E; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Klajer E; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, Besançon, France.
Molimard C; Department of Pathology, University Hospital of Besançon, Besançon, France.
Monnien F; Department of Pathology, University Hospital of Besançon, Besançon, France.
Bibeau F; Department of Pathology, University Hospital of Besançon, Besançon, France.
Turco C; Department of Surgery, University Hospital of Besançon, Besançon, France.
Heyd B; Department of Surgery, University Hospital of Besançon, Besançon, France.
Peixoto P; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; EPIGENEXP platform, University of Bourgogne Franche-Comté, Besançon, France.
Hervouet E; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; EPIGENEXP platform, University of Bourgogne Franche-Comté, Besançon, France.
Loyon R; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Doussot A; Department of Surgery, University Hospital of Besançon, Besançon, France.
Borg C; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, Besançon, France.; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Kroemer M; Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, Besançon, France.; INSERM, EFS BFC, UMR1098, RIGHT, University of Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; Department of Pharmacy, University Hospital of Besançon, Besançon, France.
DB Label
Database : MEDLINE
원문보기
Open Access (PubMed Central)  등재 - Web of Science (SCIE)  조회 - Impact Factor (JCR) 
5
Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinoma. 미리보기

학술저널

issue
Cancer immunology, immunotherapy : CII [Cancer Immunol Immunother] 2023 Mar; Vol. 72 (3), pp. 579-589. Date of Electronic Publication: 2022 Aug 21.
Author
Laheurte C; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, 25000, Besançon, France.
Seffar E; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.
Gravelin E; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, 25000, Besançon, France.
Lecuelle J; Platform of Transfer in Biological Oncology, Georges François Leclerc Cancer Center - UNICANCER, 1 rue du Professeur Marion, 21000, Dijon, France.; UMR INSERM 1231, 7 Boulevard Jeanne d'Arc, 21000, Dijon, France.
Renaudin A; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, 25000, Besançon, France.
Boullerot L; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, 25000, Besançon, France.
Malfroy M; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.
Marguier A; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.
Lecoester B; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.
Gaugler B; INSERM UMR938, Centre de Recherche Saint-Antoine (CRSA), 75012, Paris, France.
Saas P; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France.; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, 25000, Besançon, France.
Truntzer C; Platform of Transfer in Biological Oncology, Georges François Leclerc Cancer Center - UNICANCER, 1 rue du Professeur Marion, 21000, Dijon, France.; UMR INSERM 1231, 7 Boulevard Jeanne d'Arc, 21000, Dijon, France.
Ghiringhelli F; Platform of Transfer in Biological Oncology, Georges François Leclerc Cancer Center - UNICANCER, 1 rue du Professeur Marion, 21000, Dijon, France.; UMR INSERM 1231, 7 Boulevard Jeanne d'Arc, 21000, Dijon, France.
Adotevi O; INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Univ. Bourgogne Franche-Comté, 25000, Besançon, France. olivier.adotevi@univ-fcomte.fr.; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, 25000, Besançon, France. olivier.adotevi@univ-fcomte.fr.; Service Oncologie médicale, University Hospital of Besançon, 25000, Besançon, France. olivier.adotevi@univ-fcomte.fr.; INSERM UMR1098, RIGHT Institute, EFS Bourgogne Franche-Comté, 8, rue du Docteur JF-Xavier Girod, BP 1937, 25020, Besançon Cedex, France. olivier.adotevi@univ-fcomte.fr.
DB Label
Database : MEDLINE
원문보기
OA (Springer)  Open Access (PubMed Central)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
6
Distinct tumor architectures for metastatic colonization of the brain. 미리보기

issue
BioRxiv : the preprint server for biology [bioRxiv] 2023 Jan 28. Date of Electronic Publication: 2023 Jan 28.
Author
Gan S; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.; Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Macalinao DG; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Shahoei SH; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Tian L; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Jin X; Westlake Laboratory of Life Sciences and Biomedicine, Hangzhou, Zhejiang Province, 310024, China.; Research Center for Industries of the Future, School of Life Sciences, Westlake University, Hangzhou, Zhejiang Province, 310024, China.
Basnet H; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Muller JT; Developmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Atri P; Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Seffar E; Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Chatila W; Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Hadjantonakis AK; Developmental Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Schultz N; Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Brogi E; Department of Pathology, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Bale TA; Department of Pathology, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Pe'er D; Computational and Systems Biology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.; Howard Hughes Medical Institute, New York, NY 10065, USA.
Massagué J; Cancer Biology and Genetics Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
DB Label
Database : MEDLINE
7
TIE-2 Signaling Activation by Angiopoietin 2 On Myeloid-Derived Suppressor Cells Promotes Melanoma-Specific T-cell Inhibition. 미리보기

학술저널

issue
Frontiers in immunology [Front Immunol] 2022 Jul 22; Vol. 13, pp. 932298. Date of Electronic Publication: 2022 Jul 22 (Print Publication: 2022).
Author
Marguier A; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Laheurte C; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, Besançon, France.
Lecoester B; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Malfroy M; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Boullerot L; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, Besançon, France.
Renaudin A; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, Besançon, France.
Seffar E; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Kumar A; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.
Nardin C; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; Department of Dermatology, University Hospital of Besançon, Besançon, France.
Aubin F; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; Department of Dermatology, University Hospital of Besançon, Besançon, France.
Adotevi O; Univ. Bourgogne Franche-Comté, INSERM, EFS BFC, UMR1098, RIGHT Interactions Greffon-Hôte Tumeur/Ingénierie Cellulaire et Génique, Besançon, France.; INSERM CIC-1431, Clinical Investigation Center in Biotherapy, Plateforme de Biomonitoring, Besançon, France.; Service Oncologie médicale, CHU Besançon, Besançon, France.
DB Label
Database : MEDLINE
원문보기
Open Access (PubMed Central)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
8
Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia. 미리보기

학술저널

issue
Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jul; Vol. 10 (7).
Author
Trad R; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.
Warda W; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.; CanCell Therapeutics, Besancon, France.
Alcazer V; Clinical Hemaology, C.H. Lyon Sud, Lyon, France.
Neto da Rocha M; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.; CanCell Therapeutics, Besancon, France.
Berceanu A; Clinical Hematology, C.H. Univ Jean Minjoz, Besancon, France.
Nicod C; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.
Haderbache R; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.
Roussel X; Clinical Hematology, C.H. Univ Jean Minjoz, Besancon, France.
Desbrosses Y; Clinical Hematology, C.H. Univ Jean Minjoz, Besancon, France.
Daguindau E; Clinical Hematology, C.H. Univ Jean Minjoz, Besancon, France.
Renosi F; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.
Roumier C; Hematology Lab, CHU Lille, Lille, France.
Bouquet L; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.
Biichle S; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.
Guiot M; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.
Seffar E; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.
Caillot D; Clinical Hematology, CHU François Mitterrand, Dijon, France.
Depil S; Clinical Hematology, C.H. Lyon Sud, Lyon, France.
Robinet E; Lymphobank SAS, Besancon, France.
Salma Y; Laboratory of Applied Biotechnology (LBA3B), Lebanese University, Tripoli, Lebanon.
Deconinck E; Clinical Hematology, C.H. Univ Jean Minjoz, Besancon, France.
Deschamps M; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France.; CanCell Therapeutics, Besancon, France.
Ferrand C; TIMC, EFSBFC, INSERM UMR1098 RIGHT,UFC, Besancon, France christophe.ferrand@efs.sante.fr.; CanCell Therapeutics, Besancon, France.
DB Label
Database : MEDLINE
원문보기
Open Access (PubMed Central)  등재 - Web of Science (SCIE)  등재 - SCOPUS  조회 - Impact Factor (JCR) 
1 
바구니보기

QUICK LINK

  • 희망도서신청
  • 대출/연장조회
  • 서가부재도서
  • 이용교육

마이메뉴추가

QRCode
  • 개인정보호정책
  • 이메일무단수집거부
  • 도서관이용문의

    • 도서관자치위원회  원격제어  Instagram  facebook  w  kakao 플친
500-757 광주광역시 북구 용봉로 77 TEL 062)530-3571~2(대출반납실) FAX 062)530-3529
Copyright@2013 CHONNAM NATIONAL UNIVERSITY LIBRARY, All Rights Reserved.
  • 145546
  • 127370045